Abstract
Atlas Genetics has developed a point-of-care device for Chlamydia trachomatis utilizing a novel electrochemical detection principle. The assay has a time-to-result of less than 25 min. An independent preclinical validation study using 306 pretyped clinical samples determined a clinical sensitivity of 98.1% and specificity of 98.0%.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Chlamydia Infections / diagnosis
-
Chlamydia Infections / microbiology
-
Chlamydia trachomatis / genetics
-
Chlamydia trachomatis / isolation & purification*
-
Electrochemical Techniques / instrumentation*
-
Humans
-
Microfluidic Analytical Techniques / instrumentation*
-
Point-of-Care Systems*
-
Polymerase Chain Reaction / instrumentation
-
Reproducibility of Results
-
Sensitivity and Specificity